🇺🇸 FDA
Pipeline program

EVOLOCUMAB

20190184

Approved small_molecule active

Quick answer

EVOLOCUMAB for Dyslipidemia is a Approved program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
Dyslipidemia
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials